Skip to Content

Qapzola Approval Status

  • FDA approved: No
  • Brand name: Qapzola
  • Generic name: apaziquone
  • Company: Spectrum Pharmaceuticals, Inc.
  • Treatment for: Bladder Cancer

Qapzola (apaziquone) is an indolequinone bioreductive prodrug and analog of mitomycin C for intravesical instillation in the treatment of non-muscle invasive bladder cancer.

Development Status and FDA Approval Process for Qapzola

DateArticle
Sep 14, 2016FDA Advisory Committee Votes that Qapzola (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo
Feb 19, 2016Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide